Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133814 | 0.87 | SIRT2 (0.66) | MEN1KMT2ADUSP3PTPN1PTGES | |
| SCHEMBL7852509 | 0.82 | MEN1 (0.75) | MEN1KMT2APOLBDNMT1DUSP3 | |
| SCHEMBL22259948 | 0.81 | PTGES (0.77) | MEN1KMT2APOLBDNMT1NLRP3 | |
| SCHEMBL13345210 | 0.79 | PLK1 (0.65) | PTGS2MEN1KMT2APOLBPTGES | |
| SCHEMBL22260007 | 0.79 | PLK1 (0.79) | MEN1KMT2ANLRP3PTGESGAA | |
| SCHEMBL22260008 | 0.76 | MEN1 (0.66) | MEN1KMT2APOLBDNMT1DUSP3 | |
| SCHEMBL11258989 | 0.76 | KMT2A (1.00) | PTGS2MEN1KMT2APOLBNLRP3 | |
| SCHEMBL1906892 | 0.75 | DUSP3 (1.00) | MEN1KMT2APOLBDNMT1DUSP3 | |
| SCHEMBL1906889 | 0.75 | DUSP3 (1.00) | MEN1KMT2APOLBDNMT1DUSP3 | |
| SCHEMBL1906891 | 0.75 | DUSP3 (1.00) | MEN1KMT2APOLBDNMT1DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | PTGS2 3275/4885MEN1 40/4885KMT2A 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.